To read the full story, subscribe or sign in.

Takeda lands Japan rights for cabozantinib in Exelixis agreement

Feb. 23, 2017

TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib. The deal grants Takeda exclusive commercial and further clinical development rights in Japan for cabozantinib.

BioWorld

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for March 5.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for March 5.

Coronavirus vaccine/therapeutics illustration

Tonix looks to the past for the future of COVID-19 vaccines and testing

BioWorld MedTech

Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...

Braincool wins breakthrough nod for system to prevent painful chemo side effect

BioWorld MedTech

Braincool AB has scored a breakthrough device designation from the U.S. FDA for its Cooral system, a medical cooling technology for therapeutic hypothermia and...